In patients with Sjögren’s Syndrome, where the inflammatory component of the disease is more exacerbated, there is a statistically significant improvement in both signs and symptoms (p<0.05). Patients with dry eye disease treated with tivanisiran showed a statistically significant reduction in the central corneal damage (p<0.05). Sylentis has met at ARVO with recognized experts in […]
Category Archives: Uncategorized
The application of SYL1801 in eye drops could be a new therapeutic option for the treatment of retinal diseases characterized by neovascular processes, as opposed to the ocular injection used in current treatments. SYL1801 administered in eye drops reduces angiogenesis (blood vessel formation) in an animal model of laser-induced neovascularization, similar to intravitreally injected anti-VEGF […]
SYL040012 is a new compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension and preventing glaucoma. SYL040012 is a form of interference RNA (RNAi). It reduces intraocular pressure by inhibiting the expression of β-adrenergic receptors. Madrid, 6 September 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and […]
Español